Bli medlem
Bli medlem

Du är här

2017-01-26

ObsEva SA: ObsEva SA Announces Pricing of Initial Public Offering

ObsEva SA / ObsEva SA Announces Pricing of Initial Public Offering. Processed
and transmitted by Nasdaq Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
Geneva, Switzerland - January 25, 2017
- ObsEva SA (ObsEva) announced today the pricing of its initial public
offering of 6,450,000 common shares at the initial public offering price of
$15.00 per share. In addition, ObsEva has granted the underwriters an option
to purchase up to 967,500 additional common shares to cover over-allotments.
The offering is expected to close on or about January 31, 2017, subject to
customary closing conditions. ObsEva's common shares have been approved for
listing on The NASDAQ Global Select Market and are expected to begin trading
under the ticker symbol "OBSV" on January 26, 2017.

Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are
acting as joint book-running managers for the proposed offering.

A registration statement relating to the securities being sold in this
offering was declared effective by the Securities and Exchange Commission on
January 25, 2017. This offering is being made only by means of a written
prospectus forming part of the effective registration statement. A copy of
the final prospectus, when available, may be obtained for free by visiting
the SEC's website atwww.sec.gov. Alternatively, copies of the preliminary
prospectus and the final prospectus, when available, may be obtained from
Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven
Madison Avenue, New York, NY 10010, by telephone at 1-800-221-1037, or by
email atnewyork.prospectus@credit-suisse.com; from Jefferies LLC, Attention:
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
emailingProspectus_Department@Jefferies.com, or by calling 1-877-821-7388; or
from Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110 or by email atsyndicate@leerink.com, or
by calling 1-800-808-7525 ex. 6142.

This press release shall not constitute an offer to sell, or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

About ObsEva SA

ObsEva is a biopharmaceutical company innovating women's reproductive health
and pregnancy therapeutics from conception to birth. ObsEva aims to improve
upon the current treatment landscape with the development of novel, oral
medicines with potentially best-in-class safety and efficacy profiles.
Through strategic in-licensing and disciplined drug development, ObsEva has
established a clinical-stage pipeline with multiple development programs
focused on treating the symptoms associated with uterine fibroids and
endometriosis, improving clinical pregnancy and live birth rates in women
undergoing in vitro fertilization, and treating preterm labor.

MEDIA CONTACT

Liz Bryan
Spectrum Science
lbryan@spectrumscience.com

202-955-6222 x2526

COMPANY CONTACT

Delphine Renaud
ObsEva, CEO Office
delphine.renaud@obseva.ch

+41 22 552 1550

Press Release

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.